Non Hodgkin Lymphoma Clinical Trial

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Summary

The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.

View Full Description

Full Description

The primary aim is to determine a preliminary estimate of the progression-free survival of patients with T NHL who receive maintenance romidepsin at 2 years post-transplant for patients transplanted in CR1 or PR1 with standard risk histologies.

Secondary aims include:

Determine PFS at 2 yrs for patients transplanted in ≥CR/PR2 or for patients with high risk histologies.
Determine the toxicities associated with romidepsin following autologous transplantation
Determine the probability of OS at 2 years post transplant for all patients undergoing transplant
Characterize the effect of romidepsin on immune recovery post HDT-ASCT
OS and PFS 1 year after Romidespin completion

Patients who receive romidepsin after transplant will be evaluable for the primary endpoint, and will be counted towards the accrual total. Any patient who does not receive romidepsin after transplant, regardless of reason, will be replaced. We will also accrue a second cohort of 8 patients who are transplanted in >CR/PR2 and for high risk histologies to be analyzed for secondary endpoints only. This cohort will not be part of the primary endpoint and will be analyzed for summary statistics only. Patients who receive romidepsin after transplant will be counted towards the accrual total for Cohort 2. Any patient who does not receive romidepsin after transplant, regardless of reason, will be replaced.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age: Patients over age 16 who are deemed eligible for transplant by their treating physician Disease status: CR or PR required. Remission status will be assessed at the completion of induction chemotherapy and prior to enrollment on protocol.

Diagnosis: The following histologies will need to be confirmed at MSK or locally for participating sites in order to be considered for HDT-ASCT and post-transplant maintenance romidepsin:

PTCL
AITL
ALCL
EaTCL
Hepatosplenic Gamma Delta T cell lymphoma
Adult T-cell leukemia/lymphoma
Primary cutaneous gamma/delta T-cell lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Primary cutaneous anaplastic large cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
Mycosis fungoides/sezary syndrome Stem cell collection: A minimum of 2 x 106 CD34+ cells must have been collected

Laboratory test results within these ranges:

Total bilirubin <= 1.5 x ULN
AST (SGOT) and ALT (SGPT) <= 3 x ULN

Exclusion Criteria:

Diagnosis: progressive disease at transplant work-up
Prior therapy: prior autologous or allogeneic transplant
Active and uncontrolled infection at time of transplantation including active infection with Aspergillus or other mold, or HIV infection
Inadequate performance status/organ function defined by DLCO < 50% (adjusted for hgb), cardiac function as defined below, KPS < 60%.
Pregnant or breast feeding. For males and females of child-producing potential, inability to use effective contraceptive methods during the study
Prior therapy with romidepsin
Central nervous system or meningeal involvement

Any known cardiac abnormalities such as:

Congenital long QT syndrome
QTc interval ≥ 500 milliseconds
Myocardial infarction within 6 months of transplantation. Subjects with a history of myocardial infarction between 6 and 12 months prior to transplant who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate
Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min)
Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV (see Appendix 1) In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of ≥2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions (see Appendix 2) and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI
A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)
Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
Uncontrolled hypertension, defined as blood pressure (BP) of ≥160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria
Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
Patients taking drugs leading to significant QT prolongation within the specified wash out period (See Appendix 3: Medications That May Cause QTc Prolongation).
Concomitant use of CYP3A4 inhibitors

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

47

Study ID:

NCT01908777

Recruitment Status:

Active, not recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Moffitt Cancer Center
Tampa Florida, 33612, United States
Memorial Sloan Kettering Cancer Center
Basking Ridge New Jersey, , United States
Memorial Sloan Kettering Monmouth
Middletown New Jersey, 07748, United States
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack New York, 11725, United States
Memorial Sloan Kettering Westchester
Harrison New York, 10604, United States
Memorial Sloan Kettering Cancer Center
New York New York, 11065, United States
Weill Cornell Medical Center
New York New York, , United States
Memorial Sloan Kettering Nassau
Uniondale New York, 11553, United States
Fred Hutchinson Cancer Research Center (Data Collection Only)
Seattle Washington, 98109, United States
University of Washington (Data Collection Only)
Seattle Washington, 98109, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

47

Study ID:

NCT01908777

Recruitment Status:

Active, not recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.